
Siren Interactive hires more executives, moves to downtown Chicago
The Drug Supply Chain Security Act creates uncertainty about which trading partners have responsibility for product verification
Modern training technologies make the prospect of days-long training courses an obsolete practice
Real-world data sources can provide new dimensions to marketing plans
Latest ZS AccessMonitor asks, 'Who are physicians listening to?'
First to gain newly established program reviewing therapy management and chronic care
Vaccine working group tries to build consensus on temperature control and dispensing practices
Outsourced contract-administration provider highlights growth in invoicing and financial stewardship burdens
Meanwhile, competitor CSafe Global broadens its containers' usability
Airport will organize client carriers to meet new IATA standards
The drive for lower costs, safer products
Picks up Gallus Pharma, whose plants are in St. Louis and Princeton, NJ
MolecularHealth's RxAssistance evaluates patient access to commercial therapeutics and clinical trials
True 'market access' should involve coordinated approaches to patients and their healthcare providers
MDM practices are moving far beyond compliance concerns
American Airlines and India's Menzies Aviation Bobba build cold chain capacity
$8.3-billion deal is Roche’s biggest since acquiring Genentech in 2009
Cloud-based system is intended to focus reps' sales efforts more effectively
Now, CMS will publish 66% of received data on Sept. 30
Company handles distribution of 'niche' blood, chemotherapy and specialty products
Company handles distribution of 'niche' blood, chemotherapy and specialty products
The widely prescribed products will have some supply chain hiccups
Company's Ingenuity Health service monitors Seroquel XR, Abilify usage
TrialRx service analyzes and mitigates disclosure risks
Will federal legislation resolve ongoing DEA/drug-distributor conflicts?
Meanwhile, a scramble to accelerate vaccine testing ramps up
Absence of agreed-on FDA guidance keeps biosimilars off the US market even as their use grows abroad